Rigel Pharmaceuticals, Inc. Earnings Recaps
Q2 2026
Aug 7, 2026
Rigel’s shares gained 8.1% following Q2 results, driven primarily by the successful in-license and upcoming launch of VEPPANU, which expands the company’s commercial oncology portfolio and opens up a sizable new market opportunity beyond existing products.
Key takeaways
- Q2 U.S. net product sales reached $67 million, up 14% year-over-year, led by an 18% rise in TAVALISSE sales to a record $47.4 million.
- REZLIDHIA sales grew 27% to $8.9 million, supported by encouraging data on frontline use of VENCLEXTA enhancing REZLIDHIA’s adoption post-VENCLEXTA treatment.
- Collaboration revenues, including regulatory milestones for elacestrant and global launches of TAVALISSE, contributed $11.7 million.
- The in-licensing of VEPPANU, the first FDA-approved PROTAC for specific breast cancer patients, positions the company for new growth with commercial launch expected mid-August.
- Management emphasized a strategic focus on diversifying the commercial portfolio, advancing pipeline candidates like R289, and financial discipline to sustain long-term growth.
Q1 2026
May 7, 2026
Shares fell 6.6% after earnings as investors reacted negatively to the persistent first-quarter reimbursement challenges and seasonally impacted sales, signaling caution despite management's maintained full-year guidance.
Key takeaways
- Q1 2026 net product sales reached $54.9 million, up 26% year-over-year but pressured by typical seasonal reimbursement dynamics affecting January and February volumes.
- TAVALISSE sales grew 31% year-over-year to $37.3 million, aided by both stronger demand and improved gross-to-net adjustments.
- GAVRETO sales increased 7% to $9.6 million, establishing itself as a stable portfolio contributor.
- REZLIDHIA generated $8 million in net product sales, continuing growth momentum.
- Management reiterated 2026 revenue guidance of $275 million to $290 million and forecasted net income profitability, though near-term demand headwinds weighed on investor sentiment.
Q3 2025
Nov 6, 2025
Rigel Pharmaceuticals reported robust financial performance in Q3 2025, achieving record net product sales of $64.1 million, a 65% year-over-year increase, alongside significant advancements in its development pipeline.
Key takeaways
- Total revenue for Q3 2025 reached $69.5 million, reinforcing strong commercial execution and strategic pipeline expansion.
- The company raised its 2025 revenue guidance to a range of $285 million to $290 million, reflecting a growth of 55% to 59% compared to 2024.
- Rigel achieved net income of $27.9 million in Q3 and increased cash reserves to $137.1 million, maintaining strong financial discipline.
- Key products TAVALISSE, GAVRETO, and REZLIDHIA all demonstrated substantial year-over-year growth, with TAVALISSE alone generating $44.7 million in net sales.